Ignite Creation Date:
2025-12-25 @ 1:15 AM
Ignite Modification Date:
2026-01-05 @ 6:04 PM
Study NCT ID:
NCT02542293
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-09-16
First Post:
2015-08-26
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
Sponsor:
AstraZeneca
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-11-03
Start Date Type:
ACTUAL
Primary Completion Date:
2020-09-21
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2015-08-26
First Submit QC Date:
None
Study First Post Date:
2015-09-07
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2021-09-20
Results First Submit QC Date:
None
Results First Post Date:
2022-05-24
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-09-12
Last Update Post Date:
2025-09-16
Last Update Post Date Type:
ESTIMATED